Prucalopride

  • TRADE NAME: Motegrity (Shire)
  • INDICATIONS: indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
  • CLASS: Serotonin type 4 receptor agonist
  • HALF-LIFE: ~1 day

FDA APPROVAL DATE: 12/14/2018

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
insufficient data to identify any drug-associated risks

Our database has 19 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
GENITOURINARY
NEUROMUSCULAR/SKELETAL
RENAL


Page last updated 12/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric